Baidu
map

Radiology:注意力障碍及多动症患者服用哌醋甲酯后的脑白质结构变化

2020-01-06 shaosai MedSci原创

背景:哌醋甲酯(MPH)是治疗注意力障碍、多动症(ADHD)的有效药物。然而,关于其药理作用对人脑白质(WM)的影响尚不清楚。

背景:哌醋甲酯(MPH)是治疗注意力障碍、多动症(ADHD)的有效药物。然而,关于其药理作用对人脑白质(WM)的影响尚不清楚。

本研究旨在利用扩散张量成像(DTI)验证MPH是否能够对ADHDWM微结构有影响作用。

本研究纳入了50名无治疗史的男孩和49名诊断为ADHD的年轻成人患者,诊断标准参考DSMMD 第4版。两组受试者随机分为MPH或安慰剂进行治疗16周。在治疗终止前及终止后1周,对受试者行MRI检查,检查序列包括DTI。分别使用3个感兴趣区(ROI)和基于体素分析对脑WM进行测量部分各向异性(FA)变化。利用意向治疗线性混合模型进行ROC分析,利用基于排列的方法进行基于体素分析。

结果为,共有50名男孩和48名成年男性纳入研究中。FA ROI分析显示时间差异并无统计学意义。然而,基于体素分析显示用药种类、年龄和时间对左侧半球纤维、胼胝体干部外侧份具有交互影响,MPH治疗的男孩FA显着升高。接受安慰剂的男孩和年轻成年人并无相似的改变。

本研究表明,哌醋甲酯治疗4个月会影响注意力障碍、多动症男孩的脑白质纤维束,该种影响是具有依赖性的。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765813, encodeId=0a231e6581354, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jan 30 06:49:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348669, encodeId=ecd91348669c4, content=<a href='/topic/show?id=bf444306e0f' target=_blank style='color:#2F92EE;'>#多动症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43067, encryptionId=bf444306e0f, topicName=多动症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515708, encodeId=c18f1515e0830, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580269, encodeId=ff3d158026906, content=<a href='/topic/show?id=63e33990633' target=_blank style='color:#2F92EE;'>#哌醋甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39906, encryptionId=63e33990633, topicName=哌醋甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c51d16606310, createdName=ms5768352621950538, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765813, encodeId=0a231e6581354, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jan 30 06:49:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348669, encodeId=ecd91348669c4, content=<a href='/topic/show?id=bf444306e0f' target=_blank style='color:#2F92EE;'>#多动症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43067, encryptionId=bf444306e0f, topicName=多动症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515708, encodeId=c18f1515e0830, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580269, encodeId=ff3d158026906, content=<a href='/topic/show?id=63e33990633' target=_blank style='color:#2F92EE;'>#哌醋甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39906, encryptionId=63e33990633, topicName=哌醋甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c51d16606310, createdName=ms5768352621950538, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]
    2020-01-08 lq1767
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765813, encodeId=0a231e6581354, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jan 30 06:49:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348669, encodeId=ecd91348669c4, content=<a href='/topic/show?id=bf444306e0f' target=_blank style='color:#2F92EE;'>#多动症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43067, encryptionId=bf444306e0f, topicName=多动症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515708, encodeId=c18f1515e0830, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580269, encodeId=ff3d158026906, content=<a href='/topic/show?id=63e33990633' target=_blank style='color:#2F92EE;'>#哌醋甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39906, encryptionId=63e33990633, topicName=哌醋甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c51d16606310, createdName=ms5768352621950538, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765813, encodeId=0a231e6581354, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jan 30 06:49:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348669, encodeId=ecd91348669c4, content=<a href='/topic/show?id=bf444306e0f' target=_blank style='color:#2F92EE;'>#多动症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43067, encryptionId=bf444306e0f, topicName=多动症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515708, encodeId=c18f1515e0830, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580269, encodeId=ff3d158026906, content=<a href='/topic/show?id=63e33990633' target=_blank style='color:#2F92EE;'>#哌醋甲酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39906, encryptionId=63e33990633, topicName=哌醋甲酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c51d16606310, createdName=ms5768352621950538, createdTime=Wed Jan 08 06:49:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map